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**Additional file 1.** Full Study Protocol.

CDC

:   Centers for Disease Control and Prevention

HBV

:   Hepatitis B Virus

HCV

:   Hepatitis C Virus

HIV

:   Human Immunodeficiency Virus

HTLV-I/II

:   Human T-cell Lymphotropic Virus Type I/II

IgA

:   Immunoglobulin A

NHSN

:   National Healthcare Safety Network

PCR

:   Polymerase chain reaction

SARS-CoV-2

:   Severe acute respiratory syndrome coronavirus 2

T. cruzi

:   Trypanosoma cruzi

WNV

:   West Nile virus

ZIKV

:   Zika virus
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MRO is the Principal Investigator and with WIL conceived the study and led protocol development. MJC contributed to study design, and will recruit participants and coordinate plasma transfusions. CME composed the current submission and will recruit study participants. KNR will recruit study participants and coordinate plasma transfusions. EAH, JS, SLS, and BAS will oversee convalescent plasma qualification and appropriate release. BS will oversee plasma collections. TB, NM, AE, JJ, KC, and NMP contributed to study design and development of the proposal. SB, AK, ZB, AW, and DS are study coordinators who will screen participants and coordinate transfusions. BJM and SDJ will perform data collection and data entry. All authors read and approved the current submission.

This trial is funded by an unrestricted gift from Amazon. The funder played no role in the design of the study, the collection, analysis, and interpretation of data, or in writing the manuscript.

Only authorized personnel directly involved with the study will have access to the de-identified, coded, computerized database. Participant's records will be available to study investigators, the FDA, the NIH, the manufacturer of the study product, and the IRB.

The Institutional Review Board (IRB) at Columbia University Irving Medical Center approved protocol AAAS9924 on April 17, 2020. The research team certifies that this trial has received ethical approval from the appropriate ethical committee. Written, informed consent to participate will be obtained from all participants or from their legally authorized representatives.
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